NASDAQ:AXGNAxoGen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AxoGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.98 -0.25 (-3.04 %) (As of 04/8/2020 03:50 AM ET) Add Compare Share Today's Range$7.85Now: $7.98▼$8.5050-Day Range$7.68MA: $10.96▼$14.9452-Week Range$7.56Now: $7.98▼$25.84Volume703,600 shsAverage Volume411,067 shsMarket Capitalization$317.05 millionP/E RatioN/ADividend YieldN/ABeta0.63 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, AxoGen has a potential upside of 188.2% from its current price of $7.98.Amount of Analyst CoverageAxoGen has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAxoGen has received 408 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxoGen has received 293 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxoGen has received 58.20% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote “Outperform” if you believe AXGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.77% of the stock of AxoGen is held by insiders.Percentage Held by Institutions83.86% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to decrease by -24.62% in the coming year, from ($0.65) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGN Previous Symbol CUSIPN/A CIK805928 Webhttp://www.axogeninc.com/ Phone386-462-6800Debt Debt-to-Equity Ratio0.01 Current Ratio6.47 Quick Ratio5.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$106.71 million Price / Sales2.97 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book2.38Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-29,140,000.00 Net Margins-27.30% Return on Equity-19.53% Return on Assets-17.04%Miscellaneous EmployeesN/A Outstanding Shares39,731,000Market Cap$317.05 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive AXGN News and Ratings via Email Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AXGN Rates by TradingView AxoGen (NASDAQ:AXGN) Frequently Asked Questions How has AxoGen's stock been impacted by COVID-19 (Coronavirus)? AxoGen's stock was trading at $10.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXGN stock has decreased by 25.4% and is now trading at $7.98. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AxoGen? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AxoGen. When is AxoGen's next earnings date? AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for AxoGen. How were AxoGen's earnings last quarter? AxoGen, Inc (NASDAQ:AXGN) released its quarterly earnings data on Monday, February, 24th. The medical equipment provider reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The medical equipment provider earned $28.16 million during the quarter, compared to analysts' expectations of $28.10 million. AxoGen had a negative net margin of 27.30% and a negative return on equity of 19.53%. The company's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.09) EPS. View AxoGen's earnings history. What guidance has AxoGen issued on next quarter's earnings? AxoGen issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $124-128 million, compared to the consensus revenue estimate of $131.75 million. What price target have analysts set for AXGN? 5 brokers have issued twelve-month price objectives for AxoGen's stock. Their forecasts range from $21.00 to $28.00. On average, they anticipate AxoGen's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 188.2% from the stock's current price. View analysts' price targets for AxoGen. Has AxoGen been receiving favorable news coverage? News articles about AXGN stock have trended very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AxoGen earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAxoGen. Are investors shorting AxoGen? AxoGen saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,625,900 shares, an increase of 7.0% from the February 27th total of 1,520,000 shares. Based on an average daily volume of 398,500 shares, the days-to-cover ratio is presently 4.1 days. Approximately 4.5% of the company's shares are short sold. View AxoGen's Current Options Chain. Who are some of AxoGen's key competitors? Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), Viewray (VRAY), Zynex (ZYXI), TransMedics Group (TMDX), Semler Scientific (SMLR), BioLife Solutions (BLFS), Stereotaxis (STXS), Cutera (CUTR), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP) and Fc Global Realty (FCRE). What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Xilinx (XLNX), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Crispr Therapeutics (CRSP) and NVIDIA (NVDA). Who are AxoGen's key executives? AxoGen's management team includes the following people: Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)Mr. Peter J. Mariani, Chief Financial Officer (Age 55)Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)Mr. Michael Donovan, VP of Operations (Age 54)Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel. What is AxoGen's stock symbol? AxoGen trades on the NASDAQ under the ticker symbol "AXGN." How do I buy shares of AxoGen? Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AxoGen's stock price today? One share of AXGN stock can currently be purchased for approximately $7.98. How big of a company is AxoGen? AxoGen has a market capitalization of $317.05 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. View additional information about AxoGen. What is AxoGen's official website? The official website for AxoGen is http://www.axogeninc.com/. How can I contact AxoGen? AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: How Do I Invest in Dividend Stocks
